The most common adverse events reported with both treatments were mild to moderate gastrointestinal-related side effects.

The biotech disclosed Friday plans to terminate a Phase 2 study testing azelaprag with tirzepatide for weight loss following ...

Shares of BioAge Labs Inc. (BIOA) plummeted over 60% in after-hours trading on Friday, following the company's decision to ...

Tirzepatide has been shown in clinical trials to be more effective than diet and exercise support alone, and when compared ...

Data continue to show that tirzepatide, called Mounjaro for type 2 diabetes and Zepbound for weight loss, is safe and effective, but side effects remain.

BioAge Labs’ stock lost more than two-thirds of its market cap in pre-market trading Monday, poised to hit an all-time low ...

Patients lost an average of 20.2% of their weight with tirzepatide over 72 weeks versus 13.7% with semaglutide.

The researchers emphasized ... Nov. 26, 2024 — Tirzepatide, a new injectable weight-loss drug, reduced the risk of diabetes in patients with obesity and prediabetes by more than 90% over a three ...

CHICAGO, IL—Tirzepatide (Eli Lilly) significantly cut the risk of cardiovascular mortality and worsening heart failure events by nearly 40% over a median follow-up of roughly 2 years in patients with ...

M ONDAY, Nov. 18, 2024 (HealthDay News) -- For patients with obesity and prediabetes, three years of tirzepatide yields substantial and sustained weight reduction and a reduced risk for ...

The trial enrolled 751 adults with obesity or overweight conditions and at least one weight-related medical problem ...

AHA 2024 Tirzepatide Reduces Heart Failure Events ... heart failure and a preserved ejection fraction and obesity. Medscape Medical News, November 16, 2024 Novo Nordisk Says It Is Gradually ...